News

benzinga_article
2025.12.29 13:09
Theriva Biologics shares are trading higher after the company announced the European Medicines Agency provided overall agreement with the proposed Phase 3 clinical trial design of VCN-01 in metastatic pancreatic ductal adenocarcinoma.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer